

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 102 and 204 as follows:

6 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

7 Sec. 102. Definitions. As used in this Act, unless the
8 context otherwise requires:

9 (a) "Addict" means any person who habitually uses any drug,
10 chemical, substance or dangerous drug other than alcohol so as
11 to endanger the public morals, health, safety or welfare or who
12 is so far addicted to the use of a dangerous drug or controlled
13 substance other than alcohol as to have lost the power of self
14 control with reference to his or her addiction.

15 (b) "Administer" means the direct application of a
16 controlled substance, whether by injection, inhalation,
17 ingestion, or any other means, to the body of a patient,
18 research subject, or animal (as defined by the Humane
19 Euthanasia in Animal Shelters Act) by:

20 (1) a practitioner (or, in his or her presence, by his
21 or her authorized agent),

22 (2) the patient or research subject pursuant to an
23 order, or

1 (3) a euthanasia technician as defined by the Humane
2 Euthanasia in Animal Shelters Act.

3 (c) "Agent" means an authorized person who acts on behalf
4 of or at the direction of a manufacturer, distributor,
5 dispenser, prescriber, or practitioner. It does not include a
6 common or contract carrier, public warehouseman or employee of
7 the carrier or warehouseman.

8 (c-1) "Anabolic Steroids" means any drug or hormonal
9 substance, chemically and pharmacologically related to
10 testosterone (other than estrogens, progestins,
11 corticosteroids, and dehydroepiandrosterone), and includes:

- 12 (i) 3[beta],17-dihydroxy-5a-androstane,
13 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,
14 (iii) 5[alpha]-androstane-3,17-dione,
15 (iv) 1-androstenediol (3[beta],
16 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
17 (v) 1-androstenediol (3[alpha],
18 17[beta]-dihydroxy-5[alpha]-androst-1-ene),
19 (vi) 4-androstenediol
20 (3[beta],17[beta]-dihydroxy-androst-4-ene),
21 (vii) 5-androstenediol
22 (3[beta],17[beta]-dihydroxy-androst-5-ene),
23 (viii) 1-androstenedione
24 ([5alpha]-androst-1-en-3,17-dione),
25 (ix) 4-androstenedione
26 (androst-4-en-3,17-dione),

- 1 (x) 5-androstenedione
2 (androst-5-en-3,17-dione),
3 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
4 hydroxyandrost-4-en-3-one),
5 (xii) boldenone (17[beta]-hydroxyandrost-
6 1,4,-diene-3-one),
7 (xiii) boldione (androsta-1,4-
8 diene-3,17-dione),
9 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17
10 [beta]-hydroxyandrost-4-en-3-one),
11 (xv) clostebol (4-chloro-17[beta]-
12 hydroxyandrost-4-en-3-one),
13 (xvi) dehydrochloromethyltestosterone (4-chloro-
14 17[beta]-hydroxy-17[alpha]-methyl-
15 androst-1,4-dien-3-one),
16 (xvii) desoxymethyltestosterone
17 (17[alpha]-methyl-5[alpha]
18 -androst-2-en-17[beta]-ol) (a.k.a., madol),
19 (xviii) [delta]1-dihydrotestosterone (a.k.a.
20 '1-testosterone') (17[beta]-hydroxy-
21 5[alpha]-androst-1-en-3-one),
22 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
23 androstan-3-one),
24 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
25 5[alpha]-androstan-3-one),
26 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-

1 hydroxyestr-4-ene),
2 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
3 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
4 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
5 17[beta]-dihydroxyandrost-1,4-dien-3-one),
6 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
7 hydroxyandrostano[2,3-c]-furazan),
8 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one~~→~~
9 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
10 androst-4-en-3-one),
11 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
12 dihydroxy-estr-4-en-3-one),
13 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
14 hydroxy-5-androstan-3-one),
15 (xxix) mesterolone (1-methyl-17[beta]-hydroxy-
16 [5a]-androstan-3-one),
17 (xxx) methandienone (17[alpha]-methyl-17[beta]-
18 hydroxyandrost-1,4-dien-3-one),
19 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
20 dihydroxyandrost-5-ene),
21 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-
22 5[alpha]-androst-1-en-3-one),
23 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
24 dihydroxy-5a-androstane~~→~~,
25 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy
26 -5a-androstane~~→~~,

1 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-
2 dihydroxyandrost-4-ene),
3 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
4 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
5 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
6 hydroxyestra-4,9(10)-dien-3-one),
7 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
8 hydroxyestra-4,9-11-trien-3-one),
9 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
10 hydroxyandrost-4-en-3-one),
11 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-
12 hydroxyestr-4-en-3-one),
13 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
14 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
15 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
16 1-testosterone'),
17 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
18 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
19 dihydroxyestr-4-ene),
20 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-
21 dihydroxyestr-4-ene),
22 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
23 dihydroxyestr-5-ene),
24 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
25 dihydroxyestr-5-ene),
26 (xlvii) 19-nor-4,9(10)-androstadienedione

1 (estra-4,9(10)-diene-3,17-dione),
2 (xlvi) 19-nor-4-androstenedione (estr-4-
3 en-3,17-dione),
4 (xlvii) 19-nor-5-androstenedione (estr-5-
5 en-3,17-dione),
6 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
7 hydroxygon-4-en-3-one),
8 (li) norclostebol (4-chloro-17[beta]-
9 hydroxyestr-4-en-3-one),
10 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
11 hydroxyestr-4-en-3-one),
12 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
13 hydroxyestr-4-en-3-one),
14 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
15 2-oxa-5[alpha]-androstan-3-one),
16 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
17 dihydroxyandrost-4-en-3-one),
18 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
19 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
20 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-
21 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
22 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
23 (5[alpha]-androst-1-en-3-one),
24 (lix) testolactone (13-hydroxy-3-oxo-13,17-
25 secoandrosta-1,4-dien-17-oic
26 acid lactone),

1 (lx) testosterone (17[beta]-hydroxyandrost-
2 4-en-3-one),
3 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
4 diethyl-17[beta]-hydroxygon-
5 4,9,11-trien-3-one),
6 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
7 11-trien-3-one).

8 Any person who is otherwise lawfully in possession of an
9 anabolic steroid, or who otherwise lawfully manufactures,
10 distributes, dispenses, delivers, or possesses with intent to
11 deliver an anabolic steroid, which anabolic steroid is
12 expressly intended for and lawfully allowed to be administered
13 through implants to livestock or other nonhuman species, and
14 which is approved by the Secretary of Health and Human Services
15 for such administration, and which the person intends to
16 administer or have administered through such implants, shall
17 not be considered to be in unauthorized possession or to
18 unlawfully manufacture, distribute, dispense, deliver, or
19 possess with intent to deliver such anabolic steroid for
20 purposes of this Act.

21 (d) "Administration" means the Drug Enforcement
22 Administration, United States Department of Justice, or its
23 successor agency.

24 (d-5) "Clinical Director, Prescription Monitoring Program"
25 means a Department of Human Services administrative employee
26 licensed to either prescribe or dispense controlled substances

1 who shall run the clinical aspects of the Department of Human
2 Services Prescription Monitoring Program and its Prescription
3 Information Library.

4 (d-10) "Compounding" means the preparation and mixing of
5 components, excluding flavorings, (1) as the result of a
6 prescriber's prescription drug order or initiative based on the
7 prescriber-patient-pharmacist relationship in the course of
8 professional practice or (2) for the purpose of, or incident
9 to, research, teaching, or chemical analysis and not for sale
10 or dispensing. "Compounding" includes the preparation of drugs
11 or devices in anticipation of receiving prescription drug
12 orders based on routine, regularly observed dispensing
13 patterns. Commercially available products may be compounded
14 for dispensing to individual patients only if both of the
15 following conditions are met: (i) the commercial product is not
16 reasonably available from normal distribution channels in a
17 timely manner to meet the patient's needs and (ii) the
18 prescribing practitioner has requested that the drug be
19 compounded.

20 (e) "Control" means to add a drug or other substance, or
21 immediate precursor, to a Schedule whether by transfer from
22 another Schedule or otherwise.

23 (f) "Controlled Substance" means (i) a drug, substance,
24 immediate precursor, or synthetic drug in the Schedules of
25 Article II of this Act or (ii) a drug or other substance, or
26 immediate precursor, designated as a controlled substance by

1 the Department through administrative rule. The term does not
2 include distilled spirits, wine, malt beverages, or tobacco, as
3 those terms are defined or used in the Liquor Control Act of
4 1934 and the Tobacco Products Tax Act of 1995.

5 (f-5) "Controlled substance analog" means a substance:

6 (1) the chemical structure of which is substantially
7 similar to the chemical structure of a controlled substance
8 in Schedule I or II;

9 (2) which has a stimulant, depressant, or
10 hallucinogenic effect on the central nervous system that is
11 substantially similar to or greater than the stimulant,
12 depressant, or hallucinogenic effect on the central
13 nervous system of a controlled substance in Schedule I or
14 II; or

15 (3) with respect to a particular person, which such
16 person represents or intends to have a stimulant,
17 depressant, or hallucinogenic effect on the central
18 nervous system that is substantially similar to or greater
19 than the stimulant, depressant, or hallucinogenic effect
20 on the central nervous system of a controlled substance in
21 Schedule I or II.

22 (g) "Counterfeit substance" means a controlled substance,
23 which, or the container or labeling of which, without
24 authorization bears the trademark, trade name, or other
25 identifying mark, imprint, number or device, or any likeness
26 thereof, of a manufacturer, distributor, or dispenser other

1 than the person who in fact manufactured, distributed, or
2 dispensed the substance.

3 (h) "Deliver" or "delivery" means the actual, constructive
4 or attempted transfer of possession of a controlled substance,
5 with or without consideration, whether or not there is an
6 agency relationship.

7 (i) "Department" means the Illinois Department of Human
8 Services (as successor to the Department of Alcoholism and
9 Substance Abuse) or its successor agency.

10 (j) (Blank).

11 (k) "Department of Corrections" means the Department of
12 Corrections of the State of Illinois or its successor agency.

13 (l) "Department of Financial and Professional Regulation"
14 means the Department of Financial and Professional Regulation
15 of the State of Illinois or its successor agency.

16 (m) "Depressant" means any drug that (i) causes an overall
17 depression of central nervous system functions, (ii) causes
18 impaired consciousness and awareness, and (iii) can be
19 habit-forming or lead to a substance abuse problem, including
20 but not limited to alcohol, cannabis and its active principles
21 and their analogs, benzodiazepines and their analogs,
22 barbiturates and their analogs, opioids (natural and
23 synthetic) and their analogs, and chloral hydrate and similar
24 sedative hypnotics.

25 (n) (Blank).

26 (o) "Director" means the Director of the Illinois State

1 Police or his or her designated agents.

2 (p) "Dispense" means to deliver a controlled substance to
3 an ultimate user or research subject by or pursuant to the
4 lawful order of a prescriber, including the prescribing,
5 administering, packaging, labeling, or compounding necessary
6 to prepare the substance for that delivery.

7 (q) "Dispenser" means a practitioner who dispenses.

8 (r) "Distribute" means to deliver, other than by
9 administering or dispensing, a controlled substance.

10 (s) "Distributor" means a person who distributes.

11 (t) "Drug" means (1) substances recognized as drugs in the
12 official United States Pharmacopoeia, Official Homeopathic
13 Pharmacopoeia of the United States, or official National
14 Formulary, or any supplement to any of them; (2) substances
15 intended for use in diagnosis, cure, mitigation, treatment, or
16 prevention of disease in man or animals; (3) substances (other
17 than food) intended to affect the structure of any function of
18 the body of man or animals and (4) substances intended for use
19 as a component of any article specified in clause (1), (2), or
20 (3) of this subsection. It does not include devices or their
21 components, parts, or accessories.

22 (t-3) "Electronic health record" or "EHR" means an
23 electronic record of health-related information on an
24 individual that is created, gathered, managed, and consulted by
25 authorized health care clinicians and staff.

26 (t-4) "Emergency medical services personnel" has the

1 meaning ascribed to it in the Emergency Medical Services (EMS)
2 Systems Act.

3 (t-5) "Euthanasia agency" means an entity certified by the
4 Department of Financial and Professional Regulation for the
5 purpose of animal euthanasia that holds an animal control
6 facility license or animal shelter license under the Animal
7 Welfare Act. A euthanasia agency is authorized to purchase,
8 store, possess, and utilize Schedule II nonnarcotic and
9 Schedule III nonnarcotic drugs for the sole purpose of animal
10 euthanasia.

11 (t-10) "Euthanasia drugs" means Schedule II or Schedule III
12 substances (nonnarcotic controlled substances) that are used
13 by a euthanasia agency for the purpose of animal euthanasia.

14 (u) "Good faith" means the prescribing or dispensing of a
15 controlled substance by a practitioner in the regular course of
16 professional treatment to or for any person who is under his or
17 her treatment for a pathology or condition other than that
18 individual's physical or psychological dependence upon or
19 addiction to a controlled substance, except as provided herein:
20 and application of the term to a pharmacist shall mean the
21 dispensing of a controlled substance pursuant to the
22 prescriber's order which in the professional judgment of the
23 pharmacist is lawful. The pharmacist shall be guided by
24 accepted professional standards including, but not limited to
25 the following, in making the judgment:

26 (1) lack of consistency of prescriber-patient

1 relationship,

2 (2) frequency of prescriptions for same drug by one
3 prescriber for large numbers of patients,

4 (3) quantities beyond those normally prescribed,

5 (4) unusual dosages (recognizing that there may be
6 clinical circumstances where more or less than the usual
7 dose may be used legitimately),

8 (5) unusual geographic distances between patient,
9 pharmacist and prescriber,

10 (6) consistent prescribing of habit-forming drugs.

11 (u-0.5) "Hallucinogen" means a drug that causes markedly
12 altered sensory perception leading to hallucinations of any
13 type.

14 (u-1) "Home infusion services" means services provided by a
15 pharmacy in compounding solutions for direct administration to
16 a patient in a private residence, long-term care facility, or
17 hospice setting by means of parenteral, intravenous,
18 intramuscular, subcutaneous, or intraspinal infusion.

19 (u-5) "Illinois State Police" means the State Police of the
20 State of Illinois, or its successor agency.

21 (v) "Immediate precursor" means a substance:

22 (1) which the Department has found to be and by rule
23 designated as being a principal compound used, or produced
24 primarily for use, in the manufacture of a controlled
25 substance;

26 (2) which is an immediate chemical intermediary used or

1 likely to be used in the manufacture of such controlled
2 substance; and

3 (3) the control of which is necessary to prevent,
4 curtail or limit the manufacture of such controlled
5 substance.

6 (w) "Instructional activities" means the acts of teaching,
7 educating or instructing by practitioners using controlled
8 substances within educational facilities approved by the State
9 Board of Education or its successor agency.

10 (x) "Local authorities" means a duly organized State,
11 County or Municipal peace unit or police force.

12 (y) "Look-alike substance" means a substance, other than a
13 controlled substance which (1) by overall dosage unit
14 appearance, including shape, color, size, markings or lack
15 thereof, taste, consistency, or any other identifying physical
16 characteristic of the substance, would lead a reasonable person
17 to believe that the substance is a controlled substance, or (2)
18 is expressly or impliedly represented to be a controlled
19 substance or is distributed under circumstances which would
20 lead a reasonable person to believe that the substance is a
21 controlled substance. For the purpose of determining whether
22 the representations made or the circumstances of the
23 distribution would lead a reasonable person to believe the
24 substance to be a controlled substance under this clause (2) of
25 subsection (y), the court or other authority may consider the
26 following factors in addition to any other factor that may be

1 relevant:

2 (a) statements made by the owner or person in control
3 of the substance concerning its nature, use or effect;

4 (b) statements made to the buyer or recipient that the
5 substance may be resold for profit;

6 (c) whether the substance is packaged in a manner
7 normally used for the illegal distribution of controlled
8 substances;

9 (d) whether the distribution or attempted distribution
10 included an exchange of or demand for money or other
11 property as consideration, and whether the amount of the
12 consideration was substantially greater than the
13 reasonable retail market value of the substance.

14 Clause (1) of this subsection (y) shall not apply to a
15 noncontrolled substance in its finished dosage form that was
16 initially introduced into commerce prior to the initial
17 introduction into commerce of a controlled substance in its
18 finished dosage form which it may substantially resemble.

19 Nothing in this subsection (y) prohibits the dispensing or
20 distributing of noncontrolled substances by persons authorized
21 to dispense and distribute controlled substances under this
22 Act, provided that such action would be deemed to be carried
23 out in good faith under subsection (u) if the substances
24 involved were controlled substances.

25 Nothing in this subsection (y) or in this Act prohibits the
26 manufacture, preparation, propagation, compounding,

1 processing, packaging, advertising or distribution of a drug or
2 drugs by any person registered pursuant to Section 510 of the
3 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

4 (y-1) "Mail-order pharmacy" means a pharmacy that is
5 located in a state of the United States that delivers,
6 dispenses or distributes, through the United States Postal
7 Service or other common carrier, to Illinois residents, any
8 substance which requires a prescription.

9 (z) "Manufacture" means the production, preparation,
10 propagation, compounding, conversion or processing of a
11 controlled substance other than methamphetamine, either
12 directly or indirectly, by extraction from substances of
13 natural origin, or independently by means of chemical
14 synthesis, or by a combination of extraction and chemical
15 synthesis, and includes any packaging or repackaging of the
16 substance or labeling of its container, except that this term
17 does not include:

18 (1) by an ultimate user, the preparation or compounding
19 of a controlled substance for his or her own use; or

20 (2) by a practitioner, or his or her authorized agent
21 under his or her supervision, the preparation,
22 compounding, packaging, or labeling of a controlled
23 substance:

24 (a) as an incident to his or her administering or
25 dispensing of a controlled substance in the course of
26 his or her professional practice; or

1 (b) as an incident to lawful research, teaching or
2 chemical analysis and not for sale.

3 (z-1) (Blank).

4 (z-5) "Medication shopping" means the conduct prohibited
5 under subsection (a) of Section 314.5 of this Act.

6 (z-10) "Mid-level practitioner" means (i) a physician
7 assistant who has been delegated authority to prescribe through
8 a written delegation of authority by a physician licensed to
9 practice medicine in all of its branches, in accordance with
10 Section 7.5 of the Physician Assistant Practice Act of 1987,
11 (ii) an advanced practice registered nurse who has been
12 delegated authority to prescribe through a written delegation
13 of authority by a physician licensed to practice medicine in
14 all of its branches or by a podiatric physician, in accordance
15 with Section 65-40 of the Nurse Practice Act, (iii) an advanced
16 practice registered nurse certified as a nurse practitioner,
17 nurse midwife, or clinical nurse specialist who has been
18 granted authority to prescribe by a hospital affiliate in
19 accordance with Section 65-45 of the Nurse Practice Act, (iv)
20 an animal euthanasia agency, or (v) a prescribing psychologist.

21 (aa) "Narcotic drug" means any of the following, whether
22 produced directly or indirectly by extraction from substances
23 of vegetable origin, or independently by means of chemical
24 synthesis, or by a combination of extraction and chemical
25 synthesis:

26 (1) opium, opiates, derivatives of opium and opiates,

1 including their isomers, esters, ethers, salts, and salts
2 of isomers, esters, and ethers, whenever the existence of
3 such isomers, esters, ethers, and salts is possible within
4 the specific chemical designation; however the term
5 "narcotic drug" does not include the isoquinoline
6 alkaloids of opium;

7 (2) (blank);

8 (3) opium poppy and poppy straw;

9 (4) coca leaves, except coca leaves and extracts of
10 coca leaves from which substantially all of the cocaine and
11 ecgonine, and their isomers, derivatives and salts, have
12 been removed;

13 (5) cocaine, its salts, optical and geometric isomers,
14 and salts of isomers;

15 (6) ecgonine, its derivatives, their salts, isomers,
16 and salts of isomers;

17 (7) any compound, mixture, or preparation which
18 contains any quantity of any of the substances referred to
19 in subparagraphs (1) through (6).

20 (bb) "Nurse" means a registered nurse licensed under the
21 Nurse Practice Act.

22 (cc) (Blank).

23 (dd) "Opiate" means any substance having an addiction
24 forming or addiction sustaining liability similar to morphine
25 or being capable of conversion into a drug having addiction
26 forming or addiction sustaining liability.

1 (ee) "Opium poppy" means the plant of the species *Papaver*
2 *somniferum* L., except its seeds.

3 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
4 solution or other liquid form of medication intended for
5 administration by mouth, but the term does not include a form
6 of medication intended for buccal, sublingual, or transmucosal
7 administration.

8 (ff) "Parole and Pardon Board" means the Parole and Pardon
9 Board of the State of Illinois or its successor agency.

10 (gg) "Person" means any individual, corporation,
11 mail-order pharmacy, government or governmental subdivision or
12 agency, business trust, estate, trust, partnership or
13 association, or any other entity.

14 (hh) "Pharmacist" means any person who holds a license or
15 certificate of registration as a registered pharmacist, a local
16 registered pharmacist or a registered assistant pharmacist
17 under the Pharmacy Practice Act.

18 (ii) "Pharmacy" means any store, ship or other place in
19 which pharmacy is authorized to be practiced under the Pharmacy
20 Practice Act.

21 (ii-5) "Pharmacy shopping" means the conduct prohibited
22 under subsection (b) of Section 314.5 of this Act.

23 (ii-10) "Physician" (except when the context otherwise
24 requires) means a person licensed to practice medicine in all
25 of its branches.

26 (jj) "Poppy straw" means all parts, except the seeds, of

1 the opium poppy, after mowing.

2 (kk) "Practitioner" means a physician licensed to practice
3 medicine in all its branches, dentist, optometrist, podiatric
4 physician, veterinarian, scientific investigator, pharmacist,
5 physician assistant, advanced practice registered nurse,
6 licensed practical nurse, registered nurse, emergency medical
7 services personnel, hospital, laboratory, or pharmacy, or
8 other person licensed, registered, or otherwise lawfully
9 permitted by the United States or this State to distribute,
10 dispense, conduct research with respect to, administer or use
11 in teaching or chemical analysis, a controlled substance in the
12 course of professional practice or research.

13 (ll) "Pre-printed prescription" means a written
14 prescription upon which the designated drug has been indicated
15 prior to the time of issuance; the term does not mean a written
16 prescription that is individually generated by machine or
17 computer in the prescriber's office.

18 (mm) "Prescriber" means a physician licensed to practice
19 medicine in all its branches, dentist, optometrist,
20 prescribing psychologist licensed under Section 4.2 of the
21 Clinical Psychologist Licensing Act with prescriptive
22 authority delegated under Section 4.3 of the Clinical
23 Psychologist Licensing Act, podiatric physician, or
24 veterinarian who issues a prescription, a physician assistant
25 who issues a prescription for a controlled substance in
26 accordance with Section 303.05, a written delegation, and a

1 written collaborative agreement required under Section 7.5 of
2 the Physician Assistant Practice Act of 1987, an advanced
3 practice registered nurse with prescriptive authority
4 delegated under Section 65-40 of the Nurse Practice Act and in
5 accordance with Section 303.05, a written delegation, and a
6 written collaborative agreement under Section 65-35 of the
7 Nurse Practice Act, an advanced practice registered nurse
8 certified as a nurse practitioner, nurse midwife, or clinical
9 nurse specialist who has been granted authority to prescribe by
10 a hospital affiliate in accordance with Section 65-45 of the
11 Nurse Practice Act and in accordance with Section 303.05, or an
12 advanced practice registered nurse certified as a nurse
13 practitioner, nurse midwife, or clinical nurse specialist who
14 has full practice authority pursuant to Section 65-43 of the
15 Nurse Practice Act.

16 (nn) "Prescription" means a written, facsimile, or oral
17 order, or an electronic order that complies with applicable
18 federal requirements, of a physician licensed to practice
19 medicine in all its branches, dentist, podiatric physician or
20 veterinarian for any controlled substance, of an optometrist in
21 accordance with Section 15.1 of the Illinois Optometric
22 Practice Act of 1987, of a prescribing psychologist licensed
23 under Section 4.2 of the Clinical Psychologist Licensing Act
24 with prescriptive authority delegated under Section 4.3 of the
25 Clinical Psychologist Licensing Act, of a physician assistant
26 for a controlled substance in accordance with Section 303.05, a

1 written delegation, and a written collaborative agreement
2 required under Section 7.5 of the Physician Assistant Practice
3 Act of 1987, of an advanced practice registered nurse with
4 prescriptive authority delegated under Section 65-40 of the
5 Nurse Practice Act who issues a prescription for a controlled
6 substance in accordance with Section 303.05, a written
7 delegation, and a written collaborative agreement under
8 Section 65-35 of the Nurse Practice Act, of an advanced
9 practice registered nurse certified as a nurse practitioner,
10 nurse midwife, or clinical nurse specialist who has been
11 granted authority to prescribe by a hospital affiliate in
12 accordance with Section 65-45 of the Nurse Practice Act and in
13 accordance with Section 303.05 when required by law, or of an
14 advanced practice registered nurse certified as a nurse
15 practitioner, nurse midwife, or clinical nurse specialist who
16 has full practice authority pursuant to Section 65-43 of the
17 Nurse Practice Act.

18 (nn-5) "Prescription Information Library" (PIL) means an
19 electronic library that contains reported controlled substance
20 data.

21 (nn-10) "Prescription Monitoring Program" (PMP) means the
22 entity that collects, tracks, and stores reported data on
23 controlled substances and select drugs pursuant to Section 316.

24 (oo) "Production" or "produce" means manufacture,
25 planting, cultivating, growing, or harvesting of a controlled
26 substance other than methamphetamine.

1 (pp) "Registrant" means every person who is required to
2 register under Section 302 of this Act.

3 (qq) "Registry number" means the number assigned to each
4 person authorized to handle controlled substances under the
5 laws of the United States and of this State.

6 (qq-5) "Secretary" means, as the context requires, either
7 the Secretary of the Department or the Secretary of the
8 Department of Financial and Professional Regulation, and the
9 Secretary's designated agents.

10 (rr) "State" includes the State of Illinois and any state,
11 district, commonwealth, territory, insular possession thereof,
12 and any area subject to the legal authority of the United
13 States of America.

14 (rr-5) "Stimulant" means any drug that (i) causes an
15 overall excitation of central nervous system functions, (ii)
16 causes impaired consciousness and awareness, and (iii) can be
17 habit-forming or lead to a substance abuse problem, including
18 but not limited to amphetamines and their analogs,
19 methylphenidate and its analogs, cocaine, and phencyclidine
20 and its analogs.

21 (rr-10) "Synthetic drug" includes, but is not limited to,
22 any synthetic cannabinoids or piperazines or any synthetic
23 cathinones as provided for in Schedule I.

24 (ss) "Ultimate user" means a person who lawfully possesses
25 a controlled substance for his or her own use or for the use of
26 a member of his or her household or for administering to an

1 animal owned by him or her or by a member of his or her
2 household.

3 (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
4 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
5 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
6 1-1-18; revised 10-6-17.)

7 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

8 Sec. 204. (a) The controlled substances listed in this
9 Section are included in Schedule I.

10 (b) Unless specifically excepted or unless listed in
11 another schedule, any of the following opiates, including their
12 isomers, esters, ethers, salts, and salts of isomers, esters,
13 and ethers, whenever the existence of such isomers, esters,
14 ethers and salts is possible within the specific chemical
15 designation:

16 (1) Acetylmethadol;

17 (1.1) Acetyl-alpha-methylfentanyl

18 (N-[1-(1-methyl-2-phenethyl)-

19 4-piperidinyl]-N-phenylacetamide);

20 (2) Allylprodine;

21 (3) Alphacetylmethadol, except

22 levo-alphacetylmethadol (also known as levo-alpha-

23 acetylmethadol, levomethadyl acetate, or LAAM);

24 (4) Alphameprodine;

25 (5) Alphamethadol;

- 1 (6) Alpha-methylfentanyl
- 2 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
- 3 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 4 propanilido) piperidine;
- 5 (6.1) Alpha-methylthiofentanyl
- 6 (N-[1-methyl-2-(2-thienyl) ethyl-
- 7 4-piperidinyl]-N-phenylpropanamide);
- 8 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 9 (7.1) PEPAP
- 10 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 11 (8) Benzethidine;
- 12 (9) Betacetylmethadol;
- 13 (9.1) Beta-hydroxyfentanyl
- 14 (N-[1-(2-hydroxy-2-phenethyl)-
- 15 4-piperidinyl]-N-phenylpropanamide);
- 16 (10) Betameprodine;
- 17 (11) Betamethadol;
- 18 (12) Betaprodine;
- 19 (13) Clonitazene;
- 20 (14) Dextromoramide;
- 21 (15) Diampromide;
- 22 (16) Diethylthiambutene;
- 23 (17) Difenoazin;
- 24 (18) Dimenoxadol;
- 25 (19) Dimepheptanol;
- 26 (20) Dimethylthiambutene;

- 1 (21) Dioxaphetylbutyrate;
- 2 (22) Dipipanone;
- 3 (23) Ethylmethylthiambutene;
- 4 (24) Etonitazene;
- 5 (25) Etoxeridine;
- 6 (26) Furethidine;
- 7 (27) Hydroxypethidine;
- 8 (28) Ketobemidone;
- 9 (29) Levomoramide;
- 10 (30) Levophenacymorphan;
- 11 (31) 3-Methylfentanyl
12 (N-[3-methyl-1-(2-phenylethyl)-
13 4-piperidyl]-N-phenylpropanamide);
- 14 (31.1) 3-Methylthiofentanyl
15 (N-[(3-methyl-1-(2-thienyl)ethyl-
16 4-piperidinyl]-N-phenylpropanamide);
- 17 (32) Morpheridine;
- 18 (33) Noracymethadol;
- 19 (34) Norlevorphanol;
- 20 (35) Normethadone;
- 21 (36) Norpipanone;
- 22 (36.1) Para-fluorofentanyl
23 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
24 4-piperidinyl]propanamide);
- 25 (37) Phenadoxone;
- 26 (38) Phenampromide;

- 1 (39) Phenomorphan;
- 2 (40) Phenoperidine;
- 3 (41) Piritramide;
- 4 (42) Proheptazine;
- 5 (43) Properidine;
- 6 (44) Propiram;
- 7 (45) Racemoramide;
- 8 (45.1) Thiofentanyl
- 9 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 10 4-piperidinyl]-propanamide);
- 11 (46) Tilidine;
- 12 (47) Trimeperidine;
- 13 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 14 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 15 N-phenylpropanamide);
- 16 (49) Furanyl fentanyl (FU-F);
- 17 (50) Butyryl fentanyl;
- 18 (51) Valeryl fentanyl;
- 19 (52) Acetyl fentanyl;
- 20 (53) Beta-hydroxy-thiofentanyl;
- 21 (54) 3,4-dichloro-N-[2-
- 22 (dimethylamino)cyclohexyl]-N-
- 23 methylbenzamide (U-47700);
- 24 (55) 4-chloro-N-[1-[2-
- 25 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
- 26 benzenesulfonamide (W-18);

1 (56) 4-chloro-N-[1-(2-phenylethyl)
2 -2-piperidinylidene]-benzenesulfonamide (W-15);

3 (57) acrylfentanyl (acryloylfentanyl).

4 (c) Unless specifically excepted or unless listed in
5 another schedule, any of the following opium derivatives, its
6 salts, isomers and salts of isomers, whenever the existence of
7 such salts, isomers and salts of isomers is possible within the
8 specific chemical designation:

- 9 (1) Acetorphine;
- 10 (2) Acetyldihydrocodeine;
- 11 (3) Benzylmorphine;
- 12 (4) Codeine methylbromide;
- 13 (5) Codeine-N-Oxide;
- 14 (6) Cyprenorphine;
- 15 (7) Desomorphine;
- 16 (8) Diacetyldihydromorphine (Dihydroheroin);
- 17 (9) Dihydromorphine;
- 18 (10) Drotebanol;
- 19 (11) Etorphine (except hydrochloride salt);
- 20 (12) Heroin;
- 21 (13) Hydromorphanol;
- 22 (14) Methyldesorphine;
- 23 (15) Methyldihydromorphine;
- 24 (16) Morphine methylbromide;
- 25 (17) Morphine methylsulfonate;
- 26 (18) Morphine-N-Oxide;

- 1 (19) Myrophine;
- 2 (20) Nicocodeine;
- 3 (21) Nicomorphine;
- 4 (22) Normorphine;
- 5 (23) Pholcodine;
- 6 (24) Thebacon.

7 (d) Unless specifically excepted or unless listed in
8 another schedule, any material, compound, mixture, or
9 preparation which contains any quantity of the following
10 hallucinogenic substances, or which contains any of its salts,
11 isomers and salts of isomers, whenever the existence of such
12 salts, isomers, and salts of isomers is possible within the
13 specific chemical designation (for the purposes of this
14 paragraph only, the term "isomer" includes the optical,
15 position and geometric isomers):

- 16 (1) 3,4-methylenedioxyamphetamine
17 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
18 methylenedioxyamphetamine, MDA);
 - 19 (1.1) Alpha-ethyltryptamine
20 (some trade or other names: etryptamine;
21 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
22 3-(2-aminobutyl)indole; a-ET; and AET);
- 23 (2) 3,4-methylenedioxymethamphetamine (MDMA);
 - 24 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
25 (also known as: N-ethyl-alpha-methyl-
26 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

- 1 and MDEA);
- 2 (2.2) N-Benzylpiperazine (BZP);
- 3 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
- 4 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
- 5 (4) 3,4,5-trimethoxyamphetamine (TMA);
- 6 (5) (Blank);
- 7 (6) Diethyltryptamine (DET);
- 8 (7) Dimethyltryptamine (DMT);
- 9 (7.1) 5-Methoxy-diallyltryptamine;
- 10 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
- 11 (9) Ibogaine (some trade and other names:
- 12 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
- 13 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
- 14 indole; Tabernanthe iboga);
- 15 (10) Lysergic acid diethylamide;
- 16 (10.1) Salvinorin A;
- 17 (10.5) Salvia divinorum (meaning all parts of the plant
- 18 presently classified botanically as Salvia divinorum,
- 19 whether growing or not, the seeds thereof, any extract from
- 20 any part of that plant, and every compound, manufacture,
- 21 salts, isomers, and salts of isomers whenever the existence
- 22 of such salts, isomers, and salts of isomers is possible
- 23 within the specific chemical designation, derivative,
- 24 mixture, or preparation of that plant, its seeds or
- 25 extracts);
- 26 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

1 (12) Peyote (meaning all parts of the plant presently
2 classified botanically as *Lophophora williamsii* Lemaire,
3 whether growing or not, the seeds thereof, any extract from
4 any part of that plant, and every compound, manufacture,
5 salts, derivative, mixture, or preparation of that plant,
6 its seeds or extracts);

7 (13) N-ethyl-3-piperidyl benzilate (JB 318);

8 (14) N-methyl-3-piperidyl benzilate;

9 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
10 (also known as N-hydroxy-alpha-methyl-
11 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

12 (15) Parahexyl; some trade or other names:
13 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
14 dibenzo (b,d) pyran; Synhexyl;

15 (16) Psilocybin;

16 (17) Psilocyn;

17 (18) Alpha-methyltryptamine (AMT);

18 (19) 2,5-dimethoxyamphetamine
19 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

20 (20) 4-bromo-2,5-dimethoxyamphetamine
21 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
22 4-bromo-2,5-DMA);

23 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
24 Some trade or other names: 2-(4-bromo-
25 2,5-dimethoxyphenyl)-1-aminoethane;
26 alpha-desmethyl DOB, 2CB, Nexus;

- 1 (21) 4-methoxyamphetamine
2 (4-methoxy-alpha-methylphenethylamine;
3 paramethoxyamphetamine; PMA);
4 (22) (Blank);
5 (23) Ethylamine analog of phencyclidine.
6 Some trade or other names:
7 N-ethyl-1-phenylcyclohexylamine,
8 (1-phenylcyclohexyl) ethylamine,
9 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
10 (24) Pyrrolidine analog of phencyclidine. Some trade
11 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
12 PHP;
13 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
14 (26) 2,5-dimethoxy-4-ethylamphetamine
15 (another name: DOET);
16 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
17 (another name: TCPy);
18 (28) (Blank);
19 (29) Thiophene analog of phencyclidine (some trade
20 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
21 2-thienyl analog of phencyclidine; TPCP; TCP);
22 (29.1) Benzothiophene analog of phencyclidine. Some
23 trade or other names: BTCP or benocyclidine;
24 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
25 (30) Bufotenine (some trade or other names:
26 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

1 3-(2-dimethylaminoethyl)-5-indolol;
2 5-hydroxy-N,N-dimethyltryptamine;
3 N,N-dimethylserotonin; mappine);
4 (31) (Blank);
5 (32) (Blank);
6 (33) (Blank);
7 (34) (Blank);
8 (34.5) (Blank);
9 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
10 (2-methyloctan-2-yl)-6a,7,
11 10,10a-tetrahydrobenzo[c]chromen-1-ol
12 Some trade or other names: HU-210;
13 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
14 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
15 tetrahydrobenzo[c]chromen-1-ol, its isomers,
16 salts, and salts of isomers; Some trade or other
17 names: HU-210, Dexanabinol;
18 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
19 6,6-dimethyl-3-(2-methyloctan-2-yl)-
20 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
21 Some trade or other names: HU-211;
22 (37) (Blank);
23 (38) (Blank);
24 (39) (Blank);
25 (40) (Blank);
26 (41) (Blank);

1 (42) Any compound structurally derived from
2 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
3 by substitution at the nitrogen atom of the indole ring by
4 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5 cycloalkylethyl, aryl halide, alkyl aryl halide,
6 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl whether or not further substituted
8 in the indole ring to any extent, whether or not
9 substituted in the naphthyl ring to any extent. Examples of
10 this structural class include, but are not limited to,
11 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

12 (43) Any compound structurally derived from
13 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
14 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 in the pyrrole ring to any extent, whether or not
19 substituted in the naphthyl ring to any extent. Examples of
20 this structural class include, but are not limited to,
21 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

22 (44) Any compound structurally derived from
23 1-(1-naphthylmethyl)indene by substitution at the
24 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl whether or not further substituted
2 in the indene ring to any extent, whether or not
3 substituted in the naphthyl ring to any extent. Examples of
4 this structural class include, but are not limited to,
5 JWH-176;

6 (45) Any compound structurally derived from
7 3-phenylacetylindole by substitution at the nitrogen atom
8 of the indole ring with alkyl, haloalkyl, alkenyl,
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further substituted
12 in the indole ring to any extent, whether or not
13 substituted in the phenyl ring to any extent. Examples of
14 this structural class include, but are not limited to,
15 JWH-167, JWH-250, JWH-251, and RCS-8;

16 (46) Any compound structurally derived from
17 2-(3-hydroxycyclohexyl)phenol by substitution at the
18 5-position of the phenolic ring by alkyl, haloalkyl,
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
20 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not substituted in the
22 cyclohexyl ring to any extent. Examples of this structural
23 class include, but are not limited to, CP 47, 497 and its
24 C8 homologue (cannabicyclohexanol);

25 (46.1) Any compound structurally derived from
26 3-(benzoyl) indole with substitution at the nitrogen atom

1 of the indole ring by an alkyl, haloalkyl, alkenyl,
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl group whether or not further
5 substituted in the indole ring to any extent and whether or
6 not substituted in the phenyl ring to any extent. Examples
7 of this structural class include, but are not limited to,
8 AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and
9 RCS-4;

10 (47) (Blank);

11 (48) (Blank);

12 (49) (Blank);

13 (50) (Blank);

14 (51) (Blank);

15 (52) (Blank);

16 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine_

17 Some trade or other names: 2C-T-7;

18 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine_ Some trade
19 or other names: 2C-E;

20 (53.2) 2,5-dimethoxy-4-methylphenethylamine_ Some
21 trade or other names: 2C-D;

22 (53.3) 4-chloro-2,5-dimethoxyphenethylamine_ Some
23 trade or other names: 2C-C;

24 (53.4) 4-iodo-2,5-dimethoxyphenethylamine_ Some trade
25 or other names: 2C-I;

26 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine_ Some

1 trade or other names: 2C-T-2;

2 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine_

3 Some trade or other names: 2C-T-4;

4 (53.7) 2,5-dimethoxyphenethylamine_ Some trade or
5 other names: 2C-H;

6 (53.8) 2,5-dimethoxy-4-nitrophenethylamine_ Some trade
7 or other names: 2C-N;

8 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine_ Some
9 trade or other names: 2C-P;

10 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine_ Some
11 trade or other names: 2C-G;

12 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
13 phenethylamine referred to in subparagraphs (20.1), (53),
14 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
15 (53.8), (53.9), and (53.10) including, but not limited to,
16 25I-NBOMe and 25C-NBOMe;

17 (54) 5-Methoxy-N,N-diisopropyltryptamine;

18 (55) (Blank);

19 (56) (Blank);

20 (57) (Blank);

21 (58) (Blank);

22 (59) 3-cyclopropoylindole with substitution at the
23 nitrogen atom of the indole ring by alkyl, haloalkyl,
24 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
25 alkyl aryl halide, 1-(N-methyl-2-piperidiny)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indole ring to any extent, whether or not
2 substituted on the cyclopropyl ring to any extent:
3 including, but not limited to, XLR11, UR144, FUB-144;

4 (60) 3-adamantoylindole with substitution at the
5 nitrogen atom of the indole ring by alkyl, haloalkyl,
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indole ring to any extent, whether or not
10 substituted on the adamantyl ring to any extent: including,
11 but not limited to, AB-001;

12 (61) N-(adamantyl)-indole-3-carboxamide with
13 substitution at the nitrogen atom of the indole ring by
14 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indole ring to any extent, whether or not
19 substituted on the adamantyl ring to any extent: including,
20 but not limited to, APICA/2NE-1, STS-135;

21 (62) N-(adamantyl)-indazole-3-carboxamide with
22 substitution at a nitrogen atom of the indazole ring by
23 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
24 cycloalkylethyl, aryl halide, alkyl aryl halide,
25 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indazole ring to any extent, whether or not
2 substituted on the adamantyl ring to any extent: including,
3 but not limited to, AKB48, 5F-AKB48;

4 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
5 with substitution at the nitrogen atom of the indole ring
6 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
7 cycloalkylethyl, aryl halide, alkyl aryl halide,
8 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indole ring to any extent, whether or not
11 substituted on the quinoline ring to any extent: including,
12 but not limited to, PB22, 5F-PB22, FUB-PB-22;

13 (64) 3-(1-naphthoyl)indazole with substitution at the
14 nitrogen atom of the indazole ring by alkyl, haloalkyl,
15 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
16 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indazole ring to any extent, whether or not
19 substituted on the naphthyl ring to any extent: including,
20 but not limited to, THJ-018, THJ-2201;

21 (65) 2-(1-naphthoyl)benzimidazole with substitution at
22 the nitrogen atom of the benzimidazole ring by alkyl,
23 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
24 aryl halide, alkyl aryl halide,
25 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the benzimidazole ring to any extent, whether or not
2 substituted on the naphthyl ring to any extent: including,
3 but not limited to, FUBIMINA;

4 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
5 3-carboxamide with substitution on the nitrogen atom of the
6 indazole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indazole ring to any extent: including, but not
11 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

12 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
13 indazole-3-carboxamide with substitution on the nitrogen
14 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indazole ring to any extent: including, but not
19 limited to, ADB-PINACA, ADB-FUBINACA;

20 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
21 indole-3-carboxamide with substitution on the nitrogen
22 atom of the indole ring by alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indole ring to any extent: including, but not

1 limited to, ADBICA, 5F-ADBICA;

2 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
3 3-carboxamide with substitution on the nitrogen atom of the
4 indole ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6 halide, 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further substituted
8 on the indole ring to any extent: including, but not
9 limited to, ABICA, 5F-ABICA;

10 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
11 methylbutanoate with substitution on the nitrogen atom of
12 the indazole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14 halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indazole ring to any extent: including, but not
17 limited to, AMB, 5F-AMB;

18 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
19 dimethylbutanoate with substitution on the nitrogen atom
20 of the indazole ring by alkyl, haloalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent: including, but not
25 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

26 (72) Methyl 2-(1H-indole-3-carboxamido)-3-

1 methylbutanoate with substitution on the nitrogen atom of
2 the indole ring by alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indazole ring to any extent: including, but not
7 limited to, MMB018, MMB2201, and AMB-CHMICA;

8 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
9 dimethylbutanoate with substitution on the nitrogen atom
10 of the indole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the indazole ring to any extent: including, but not
15 limited to, MDMB-CHMICA;

16 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
17 indazole-3-carboxamide with substitution on the nitrogen
18 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further substituted
22 on the indazole ring to any extent: including, but not
23 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

24 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
25 3-carboxamide with substitution on the nitrogen atom of the
26 indole ring by alkyl, haloalkyl, alkenyl,

1 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2 halide, 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not further substituted
4 on the indazole ring to any extent: including, but not
5 limited to, APP-PICA and 5-fluoro-APP-PICA;

6 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
7 4-AcO-DMT;

8 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
9 name 5-MeO-MIPT;

10 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

11 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

12 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

13 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
14 (4-HO-MiPT);

15 (82) Fluorophenylpiperazine;

16 (83) Methoxetamine;

17 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
18 ethcathinone).

19 (e) Unless specifically excepted or unless listed in
20 another schedule, any material, compound, mixture, or
21 preparation which contains any quantity of the following
22 substances having a depressant effect on the central nervous
23 system, including its salts, isomers, and salts of isomers
24 whenever the existence of such salts, isomers, and salts of
25 isomers is possible within the specific chemical designation:

26 (1) mecloqualone;

1 (2) methaqualone; and

2 (3) gamma hydroxybutyric acid.

3 (f) Unless specifically excepted or unless listed in
4 another schedule, any material, compound, mixture, or
5 preparation which contains any quantity of the following
6 substances having a stimulant effect on the central nervous
7 system, including its salts, isomers, and salts of isomers:

8 (1) Fenethylline;

9 (2) N-ethylamphetamine;

10 (3) Aminorex (some other names:

11 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

12 4-5-dihydro-5-phenyl-2-oxazolamine) and its

13 salts, optical isomers, and salts of optical isomers;

14 (4) Methcathinone (some other names:

15 2-methylamino-1-phenylpropan-1-one;

16 Ephedrone; 2-(methylamino)-propiofenone;

17 alpha-(methylamino)propiofenone; N-methylcathinone;

18 methcathinone; Monomethylpropion; UR 1431) and its

19 salts, optical isomers, and salts of optical isomers;

20 (5) Cathinone (some trade or other names:

21 2-aminopropiofenone; alpha-aminopropiofenone;

22 2-amino-1-phenyl-propanone; norephedrone);

23 (6) N,N-dimethylamphetamine (also known as:

24 N,N-alpha-trimethyl-benzeneethanamine;

25 N,N-alpha-trimethylphenethylamine);

26 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

- 1 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
- 2 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);
- 3 (9) Halogenated amphetamines and
- 4 methamphetamines - any compound derived from either
- 5 amphetamine or methamphetamine through the substitution
- 6 of a halogen on the phenyl ring, including, but not
- 7 limited to, 2-fluoroamphetamine, 3-
- 8 fluoroamphetamine and 4-fluoroamphetamine;
- 9 (10) Aminopropylbenzofuran (APB):
- 10 including 4-(2-Aminopropyl) benzofuran, 5-
- 11 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
- 12 benzofuran, and 7-(2-Aminopropyl) benzofuran;
- 13 (11) Aminopropyldihydrobenzofuran (APDB):
- 14 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
- 15 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
- 16 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
- 17 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
- 18 (12) Methylaminopropylbenzofuran
- 19 (MAPB): including 4-(2-methylaminopropyl)
- 20 benzofuran, 5-(2-methylaminopropyl)benzofuran,
- 21 6-(2-methylaminopropyl)benzofuran
- 22 and 7-(2-methylaminopropyl)benzofuran.
- 23 (g) Temporary listing of substances subject to emergency
- 24 scheduling. Any material, compound, mixture, or preparation
- 25 that contains any quantity of the following substances:
- 26 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide

1 (benzylfentanyl), its optical isomers, isomers, salts, and
2 salts of isomers;

3 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
4 phenylpropanamide (thenylfentanyl), its optical isomers,
5 salts, and salts of isomers.

6 (h) Synthetic cathinones. Unless specifically excepted,
7 any chemical compound which is not approved by the United
8 States Food and Drug Administration or, if approved, is not
9 dispensed or possessed in accordance with State or federal law,
10 not including bupropion, structurally derived from
11 2-aminopropan-1-one by substitution at the 1-position with
12 either phenyl, naphthyl, or thiophene ring systems, whether or
13 not the compound is further modified in one or more of the
14 following ways:

15 (1) by substitution in the ring system to any extent
16 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
17 halide substituents, whether or not further substituted in
18 the ring system by one or more other univalent
19 substituents. Examples of this class include, but are not
20 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

21 (2) by substitution at the 3-position with an acyclic
22 alkyl substituent. Examples of this class include, but are
23 not limited to, 2-methylamino-1-phenylbutan-1-one
24 (buphedrone); or

25 (3) by substitution at the 2-amino nitrogen atom with
26 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by

1 inclusion of the 2-amino nitrogen atom in a cyclic
2 structure. Examples of this class include, but are not
3 limited to, Dimethylcathinone, Ethcathinone, and
4 a-Pyrrolidinopropiophenone (a-PPP); ~~or~~

5 Any other synthetic cathinone which is not approved by the
6 United States Food and Drug Administration or, if approved, is
7 not dispensed or possessed in accordance with State or federal
8 law.

9 (i) Synthetic cannabinoids or piperazines. Any synthetic
10 cannabinoid or piperazine which is not approved by the United
11 States Food and Drug Administration or, if approved, which is
12 not dispensed or possessed in accordance with State and federal
13 law.

14 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
15 100-368, eff. 1-1-18; revised 10-5-17.)